Ten studies from 2013 with potential to change endocrinology practice were summarized in Annals of Internal Medicine's annual Update in Endocrinology, published in the June 3 issue.
The authors of a systematic review and meta-analysis recommended reconsideration of guidelines on sodium-glucose cotransporter-2 (SGLT-2) inhibitors to increase use among patients at risk of cardiovascular disease.
About one-third of men approached in barbershops owned by black individuals were willing to be screened for diabetes, and 9% of them had undiagnosed diabetes while 28% had prediabetes.
While weight loss and improved fitness should both be recommended for patients with diabetes, these observational results highlight the need for further research to test whether prevention strategies focusing on improving
Incorporating intensive weight management with a low-carb diet into standard group medical visits for patients with diabetes “should be considered as an alternative, noninferior approach for glycemic management that has additional clinical
They pointed out that almost 50% of patients with diabetes have severe periodontitis and that their findings “highlight the potential to improve metabolic control and possibly diabetes outcomes by addressing poor
Other independent predictors of long-term weight loss included greater weight loss in the first year and older age, according to this follow-up analysis of the Diabetes Prevention Program.
Patients were more likely to choose more intensive care after an annual consultation if they had a high level of education, if they were concerned about illness, if they had set goals for their care, and if they had comorbid conditions.
Patients with type 1 diabetes who were randomly assigned to insulin treatment with a closed-loop system spent more time in the target glycemic range than those assigned to a sensor-augmented pump.
The industry-funded PIONEER 3 trial randomized adults whose type 2 diabetes was uncontrolled with metformin, with or without sulfonylurea, to receive either oral sitagliptin (100 mg/d) or oral semaglutide (3, 7, or 14 mg/d).